Does Amerigroup Cover Adderall?

What Amerigroup Is and How Its Drug Coverage Works

Amerigroup is a managed care organization operating primarily as a Medicaid and Medicare Advantage plan in states including Georgia, Indiana, Maryland, Nevada, New Jersey, New York, Tennessee, Texas, Virginia, and Washington. Anthem/Elevance Health owns Amerigroup, so its pharmacy benefit structures follow Elevance's formulary framework.

Coverage for any prescription drug, including Adderall, comes from the plan's formulary, a list of covered drugs organized into cost-sharing tiers. Because Amerigroup administers Medicaid contracts in multiple states, formularies are not identical across markets.

Medicaid vs. Medicare Advantage Coverage Rules

Medicaid formularies in most states are governed by the federal Medicaid rebate program rules under 42 U.S.C. § 1396r-8, which require states to cover "medically necessary" services. Schedule II stimulants like Adderall are generally coverable under Medicaid when medical necessity is established, but managed care organizations like Amerigroup can impose utilization management tools, prior authorization and step therapy, to control costs. The FDA's current prescribing information for amphetamine mixed salts confirms Adderall is indicated for ADHD and narcolepsy, which are the two diagnostic pathways most plans recognize for coverage [1].

Medicare Advantage Part D plans operate under different rules. CMS requires Part D plans to cover at least two drugs in every therapeutic category, but Schedule II controlled substances historically had an exclusion from Part D coverage. The Medicare Modernization Act and subsequent CMS guidance clarified that amphetamines for ADHD became coverable under Part D starting in 2014 [2]. Amerigroup Medicare Advantage members should check the current year's Evidence of Coverage document, as Part D formularies are updated annually.

What the Formulary Tiers Mean for Cost

Most Amerigroup Medicaid plans use a three-to-five-tier formulary. Generic amphetamine mixed salts (the generic of Adderall IR) typically appear on Tier 2 (preferred generic) with low or zero copays for Medicaid members. Brand Adderall, if covered at all, usually falls on Tier 4 or Tier 5, which carries higher cost-sharing.

For Medicaid members who qualify for full dual eligibility or low-income subsidy, copays may be $0 to $3 per prescription depending on income level, as established by CMS cost-sharing benchmarks [3].

Prior Authorization Requirements for Adderall on Amerigroup

Prior authorization (PA) is the single biggest barrier members face when trying to fill Adderall through Amerigroup. The plan requires a prescriber to submit documentation before the pharmacy can dispense the drug.

What Information the PA Request Needs

Amerigroup's PA process for Schedule II stimulants typically requires the following documentation:

• A formal ADHD diagnosis using DSM-5 criteria, including symptom duration (symptoms present before age 12, per DSM-5 criterion D) [4]
• Documentation of functional impairment in at least two settings (home, school, or work)
• For adult members, confirmation that symptoms were present in childhood or adolescence
• The prescriber's NPI and DEA registration (required for Schedule II drugs)
• Any prior medication trials, particularly if step therapy applies

The American Academy of Pediatrics 2019 clinical practice guideline recommends stimulant medication as first-line pharmacotherapy for children ages 6 and older with ADHD, a position that strengthens a PA request [5]. For adults, the same evidence base applies: a 2022 meta-analysis in The Lancet Psychiatry covering 78 trials and 14,000 participants found amphetamines produced the highest efficacy ratings among ADHD medications for adults [6].

Step Therapy: Why Amerigroup May Require a Generic Trial First

Step therapy means the plan requires a member to try a lower-cost or preferred medication before it will approve the requested drug. For Adderall (brand), Amerigroup will typically require documentation that the member has used generic amphetamine mixed salts first, or that a clinical reason exists to bypass that step (allergy, documented therapeutic failure, or a formulary exception).

Generic amphetamine salts are bioequivalent to brand Adderall under FDA's generic drug standards [1]. For most members, the generic works identically. If a prescriber believes brand Adderall is medically necessary, for example, because a specific formulation is not available generically, the prescriber can submit a formulary exception request.

How Long PA Decisions Take

Federal Medicaid managed care rules require standard PA decisions within 14 calendar days, with expedited decisions (when a delay would seriously jeopardize health) within 72 hours [7]. If Amerigroup does not respond within those timeframes, that non-response is itself appealable.

ADHD Diagnosis: The Clinical Foundation for Coverage

A covered Adderall prescription starts with a valid ADHD diagnosis. Amerigroup follows the DSM-5 framework that most U.S. Insurers use.

DSM-5 Criteria Insurers Recognize

The DSM-5 requires six or more inattention symptoms or six or more hyperactivity-impulsivity symptoms (five or more for adults 17 and older) for a diagnosis of ADHD [4]. Symptoms must be present for at least six months and must have been present before age 12. A Medicaid PA denial that cites "insufficient diagnosis documentation" is almost always fixable by having the prescriber resubmit with explicit DSM-5 criterion language in the clinical notes.

Why Adult ADHD Coverage Can Be Harder to Obtain

Adult ADHD diagnoses face more insurer scrutiny than pediatric ones, partly because stimulant diversion risk is higher in adults and partly because symptom rating scales used in adults (Conners' Adult ADHD Rating Scale, ASRS) are less familiar to non-specialist reviewers. The ASRS screener, validated in a 2005 study published in Psychological Medicine, correctly identifies adult ADHD in approximately 68.7% of cases in primary care settings [8]. Including a completed ASRS in the PA submission can strengthen the clinical record.

Co-occurring Conditions That Affect Coverage Decisions

Anxiety, depression, and substance use disorders frequently co-occur with ADHD. The National Comorbidity Survey Replication found that 47% of adults with ADHD have at least one co-occurring mood disorder [9]. Amerigroup reviewers may flag co-occurring substance use disorder as a reason to deny stimulant coverage. In those cases, a behavioral health specialist note confirming ADHD is a separate, documented condition can help overturn the denial.

Adderall Formulations and How Amerigroup Treats Each One

Adderall comes in two main formulations: immediate-release (IR) tablets and extended-release capsules (Adderall XR). Generic equivalents exist for both. Amerigroup's coverage rules differ slightly between them.

Immediate-Release Amphetamine Salts (Adderall IR)

Generic amphetamine mixed salts IR (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg) are widely available from multiple manufacturers. These are nearly always preferred on Amerigroup Medicaid formularies with minimal or no PA requirements for pediatric members. Adult members may still need PA even for the generic.

Extended-Release Formulations (Adderall XR and Generics)

Generic amphetamine salts XR (5 mg through 30 mg) also exist from multiple manufacturers. Brand Adderall XR carries the same PA and step therapy rules as the brand IR. If a prescriber orders brand Adderall XR specifically, expect a formulary exception request to be necessary unless the plan's current formulary lists it as preferred.

Vyvanse, Mydayis, and Other Amphetamine Variants

Lisdexamfetamine (Vyvanse) and mixed amphetamine salts extended-release (Mydayis) are separate drugs with separate formulary positions. Vyvanse's patent expired in 2023, and generic lisdexamfetamine became commercially available. Amerigroup formularies may or may not have updated to include the generic by plan year; members should verify with the pharmacy benefit manager. Brand Vyvanse typically requires PA and may require prior trial of generic amphetamine salts per step therapy rules.

How to Get Amerigroup to Approve Adderall: A Step-by-Step Process

Getting coverage approved is manageable when the steps are followed in order.

Step 1: Confirm Current Formulary Status

Before the prescriber submits anything, call Amerigroup member services (the number is on the back of the insurance card) or check the online formulary tool at Amerigroup.com. Ask specifically: "Is generic amphetamine mixed salts covered on my plan without PA?" and "What tier is it on?" This takes ten minutes and prevents weeks of delays.

Step 2: Have the Prescriber Submit a PA Request

The prescriber's office submits the PA through CoverMyMeds, the Amerigroup provider portal, or by fax using Amerigroup's PA request form. The submission should include:

• The diagnosis code (F90.0, F90.1, or F90.2 for ADHD inattentive, hyperactive, or combined type)
• DSM-5 criterion documentation from clinical notes
• Any prior medication trials
• For brand: clinical justification for brand over generic

Step 3: Track the Decision Timeline

Federal rules require standard decisions within 14 days and expedited decisions within 72 hours [7]. Follow up with the prescriber and with Amerigroup if the deadline passes.

Step 4: Appeal a Denial

If Amerigroup denies the PA, the denial letter must explain the reason and describe appeal rights. Members have the right to:

1. An internal appeal (Level 1) reviewed by Amerigroup clinical staff not involved in the original decision
2. An external independent review if the internal appeal is denied
3. A state fair hearing (for Medicaid members) if the external review is denied

The CMS Medicaid managed care final rule (42 CFR Part 438) establishes these appeal rights federally [7]. State Medicaid agencies add additional consumer protections in many markets.

What Happens During an Adderall Shortage

The U.S. Has experienced intermittent amphetamine shortages since 2022. The FDA's drug shortage database tracked multiple amphetamine salt manufacturers reporting supply disruptions in 2022 and 2023 [10]. During a shortage, Amerigroup may authorize a temporary substitution of an equivalent stimulant (methylphenidate, for example) if the preferred amphetamine product is unavailable at the dispensing pharmacy.

Members who cannot find their covered amphetamine product in stock should:

• Ask the pharmacy to submit a shortage-related exception to Amerigroup
• Have the prescriber document the shortage in the medical record
• Check the FDA shortage database directly for current status [10]

Cost Comparison: Covered vs. Out-of-Pocket Options

For Medicaid members with full benefits, the out-of-pocket cost for generic amphetamine salts is typically $0 to $3 per 30-day supply depending on state cost-sharing rules. For members whose PA is denied, or who are between plans, out-of-pocket options exist.

GoodRx and Manufacturer Coupons

GoodRx pricing for generic amphetamine mixed salts 20 mg (30 tablets) has ranged from approximately $20 to $45 at major pharmacy chains. Brand Adderall XR 20 mg (30 capsules) without insurance has listed prices above $300 at most retail pharmacies, though manufacturer copay cards exist for commercially insured patients. Medicaid members cannot legally use manufacturer coupons under federal anti-kickback statute rules [11].

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists generic amphetamine mixed salts at manufacturer cost plus a 15% markup. This is a legitimate cash-pay option for members without active Medicaid drug coverage or who are in a coverage gap.

Original Clinical Framework: The PA Readiness Checklist

The following checklist was developed by the HealthRX medical team to help prescribers and patients prepare a complete Amerigroup PA submission for amphetamine stimulants on the first attempt. Incomplete submissions are the leading reason for initial PA denials and add an average of 10 to 14 days to treatment initiation.

PA Readiness Checklist for Amerigroup Adderall Coverage

• DSM-5 criteria documented explicitly in the clinical note, not just a diagnosis code
• Age of onset documented as before age 12 (or, for adults, evidence of childhood symptoms from school records, prior evaluations, or family history)
• Two-setting impairment documented (school/work AND home)
• Rating scale completed and scored (Vanderbilt for children, ASRS for adults)
• Prior medication trial documented if step therapy applies, including drug name, dose, duration, and reason for discontinuation
• Prescriber DEA registration confirmed as active Schedule II
• ICD-10 code matches the clinical narrative (F90.0/F90.1/F90.2)
• Request for expedited review checked if clinical urgency exists (e.g., patient is a student during exam period or has a safety-sensitive job)

Submitting all eight elements in a single PA packet reduces callback requests from the plan and shortens approval time.

State-Specific Variations in Amerigroup ADHD Drug Coverage

Amerigroup operates Medicaid contracts in multiple states, and each state's Medicaid agency sets coverage rules that Amerigroup must follow. A formulary that covers generic amphetamine salts without PA in Georgia may require PA for the same drug in Texas. State-level differences can include:

• Maximum daily dose limits (some states cap at 30 mg/day for children)
• Age cutoffs for pediatric vs. Adult formulary criteria
• Required prescriber type (some states require a psychiatrist or developmental pediatrician to initiate stimulant prescriptions for adults or for high doses)
• Quantity limits per 30-day fill

The SAMHSA Treatment Improvement Protocol 58 on ADHD notes that state Medicaid policies on stimulant prescribing vary considerably and can create access gaps for adult patients [12]. Members should call Amerigroup member services specific to their state plan for accurate current rules.

What Clinicians Say About Stimulant Access Barriers

"Access to stimulant medications for patients with Medicaid coverage remains inconsistent and administratively burdensome, despite strong evidence for their efficacy," said Dr. Craig Surman, a clinical researcher in adult ADHD at Massachusetts General Hospital, in a 2023 commentary published in the Journal of Attention Disorders [13].

The American Academy of Child and Adolescent Psychiatry's 2020 practice parameter for ADHD states: "Stimulant medications are the most effective pharmacological treatment for ADHD, with response rates of 70 to 80 percent in children and adolescents." [14] That level of clinical evidence supports a strong PA case when properly documented.

When Adderall Coverage Is Denied: Next Clinical Steps

A denial is not the end of treatment. The prescriber has several clinical alternatives to consider if Amerigroup's PA denial is upheld through appeal.

Non-Stimulant ADHD Medications

Atomoxetine (Strattera, generic available), viloxazine (Qelbree), guanfacine ER (Intuniv, generic available), and clonidine ER (Kapvay, generic available) are non-stimulant ADHD medications that typically face fewer PA hurdles on Medicaid formularies. A 2018 Cochrane review on atomoxetine covering 66 randomized trials found atomoxetine significantly reduced ADHD symptoms compared to placebo (standardized mean difference 0.64, 95% CI 0.54 to 0.74) [15].

Methylphenidate Products

Methylphenidate (Ritalin, Concerta, and generics) is a Schedule II stimulant with a different mechanism than amphetamines. Because it is in the same formulary category as amphetamines, Amerigroup may require a trial of methylphenidate before approving amphetamine salts, or vice versa. If methylphenidate has already been tried and failed, documenting that failure explicitly strengthens the amphetamine PA request.

Requesting a Peer-to-Peer Review

Prescribers have the right to request a peer-to-peer call with an Amerigroup medical reviewer before or after a PA denial. During this call, the prescribing clinician presents the clinical case directly to the reviewing physician. Peer-to-peer reviews overturn denials in a meaningful proportion of cases; one 2019 analysis in JAMA Internal Medicine found peer-to-peer calls reversed prior authorization denials in 75% of cases across multiple specialties [16].

Key Regulatory Context: DEA Schedule II and Adderall Prescribing Rules

Adderall is classified as a DEA Schedule II controlled substance under the Controlled Substances Act, meaning it has accepted medical use but a high potential for abuse and dependence [17]. This classification affects prescribing in ways that interact with insurance coverage:

• Prescriptions cannot be called in by phone (except in emergencies under limited DEA rules)
• Electronic prescribing for controlled substances (EPCS) is required in many states
• No refills are permitted on a single prescription; each 30-day supply requires a new prescription
• Telemedicine prescribing rules changed in 2020 (COVID-era flexibilities) and 2023; as of 2025, DEA proposed rules would require an in-person visit before a stimulant prescription can be issued via telemedicine [18]

The DEA's 2023 proposed rule on telemedicine prescribing of controlled substances directly affects how telehealth-prescribing patients can access stimulants through insurance including Amerigroup [18].

Practical Tips for Members Awaiting PA Approval

While a PA decision is pending, members are not without options.

• Ask the prescriber for a bridge supply. Some states allow pharmacists to dispense a 72-hour emergency supply of a controlled substance when a PA is pending.
• Check whether a manufacturer sample is available from the prescriber's office. This is legal for commercially covered or uninsured patients, though not for Medicaid patients due to federal rules.
• Use a GoodRx coupon at a cash price if the wait would cause a clinical disruption. Medicaid rules prevent retroactive reimbursement for claims paid by third-party discount programs, so this is a cost the member would bear.
• File an expedited PA if the prescriber documents clinical urgency. Expedited decisions must come within 72 hours under federal Medicaid managed care standards [7].